• Aptiv: Guggenheim maintains its buy recommendation with a price target raised from 92 to USD 94.
  • Ares Management: TD Cowen initiates a buy recommendation with a target price of USD 154.
  • Axon Enterprise: Craig-Hallum maintains its buy recommendation and raises the price target from 325 to USD 370.
  • Block: BNP Paribas Exane maintains its outperform recommendation and reduces the target price from USD 106 to USD 100.
  • Constellation Energy: RBC Capital maintains its sector perform recommendation and raises the target price from USD 119 to USD 211.
  • Corning: Mizuho Securities initiates a neutral recommendation with a target price of USD 36.
  • CVS Health: Wells Fargo maintains its equalweight recommendation and reduces the target price from USD 76 to USD 60.
  • Exelon: RBC Capital maintains its sector perform recommendation with a price target raised from USD 37 to USD 41.
  • Lowe's Companies: Citigroup remains neutral recommendation with a price target reduced from 243 to USD 240.
  • Microchip Technology: Needham maintains its buy recommendation and raises the target price from USD 90 to USD 100.
  • Nvidia: Goldman Sachs maintains its buy recommendation and raises the target price from USD 1000 to USD 1100.
  • Palantir Technologies: Citigroup remains neutral recommendation with a price target raised from 23 to USD 25.
  • Quanta Services: Evercore ISI maintains its outperform recommendation and raises the target price from USD 255 to USD 288.
  • Rollins: Redburn Atlantic maintains a neutral recommendation with a price target raised from USD 35 to USD 37.
  • Target: Citi upgrades to buy from neutral with a target price of USD 180.
  • The Home Depot: Citigroup maintains its buy recommendation with a price target reduced from USD 415 to USD 395.
  • Tyson Foods: BMO Capital Markets maintains its market perform recommendation and raises the target price from 55 to USD 58.
  • Ventas: Evercore ISI maintains its outperform recommendation and raises the target price from USD 50 to USD 51.
  • Vertex Pharmaceuticals: Stifel maintains its hold recommendation with a price target reduced from USD 430 to USD 420.
  • Westlake: Piper Sandler & Co maintains its overweight recommendation and raises the price target from 160 to USD 180.